These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32992377)

  • 21. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.
    Xu L; Lu W; Li P; Shen F; Mi YQ; Fan JG
    Dig Liver Dis; 2017 Aug; 49(8):910-917. PubMed ID: 28433586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
    Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
    United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
    Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
    Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.
    Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Dal Bello B; Filice G; Filice C
    World J Gastroenterol; 2014 Jun; 20(21):6626-31. PubMed ID: 24914387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease.
    Andrade P; Rodrigues S; Rodrigues-Pinto E; Gaspar R; Lopes J; Lopes S; Macedo G
    GE Port J Gastroenterol; 2017 Jul; 24(4):161-168. PubMed ID: 29255745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
    Ni XX; Lian M; Wu HM; Li XY; Sheng L; Bao H; Miao Q; Xiao X; Guo CJ; Li H; Ma X; Hua J
    World J Gastroenterol; 2021 Jan; 27(1):80-91. PubMed ID: 33505152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discordance in steatosis classification between liver biopsy and transient elastography for high controlled attenuation parameter (CAP) values.
    Galaski J; Schulz L; Krause J; Lohse AW
    Z Gastroenterol; 2018 Jan; 56(1):36-42. PubMed ID: 29316576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees.
    Kim JK; Lee KS; Choi JR; Chung HJ; Jung DH; Lee KA; Lee JI
    Gut Liver; 2015 May; 9(3):405-10. PubMed ID: 25717046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
    Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
    Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of Controlled Attenuation Parameter for Identification and Grading of Nonalcoholic Fatty Liver Disease in Adolescents with Obesity.
    Anand A; Shalimar ; Jana M; Kandasamy D; Kumar B; Singh G; Jain V
    Indian J Pediatr; 2022 Jan; 89(1):52-58. PubMed ID: 34324132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
    Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
    J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease.
    Kuroda H; Abe T; Fujiwara Y; Nagasawa T; Takikawa Y
    J Med Ultrason (2001); 2021 Oct; 48(4):471-480. PubMed ID: 34415481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation.
    Welman CJ; Saunders J; Zelesco M; Abbott S; Boardman G; Ayonrinde OT
    J Med Imaging Radiat Oncol; 2023 Feb; 67(1):45-53. PubMed ID: 35466506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease.
    Fujiwara Y; Kuroda H; Abe T; Ishida K; Oguri T; Noguchi S; Sugai T; Kamiyama N; Takikawa Y
    Ultrasound Med Biol; 2018 Nov; 44(11):2223-2232. PubMed ID: 30077415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
    J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
    Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
    J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic Steatosis in Chronic Hepatitis B as Measured by Controlled Attenuation Parameter: Frequency and Distribution.
    Nan S; Liang Y; Qu Y; Liu F; Wang L; Li T
    J Coll Physicians Surg Pak; 2019 Oct; 29(10):937-941. PubMed ID: 31564265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
    Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
    EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.